Skip to Content
  • Previous Rank-
  • Revenue 3 Yr Annual Growth Rate18%
  • Revenue 3 Yr Growth Rank88
  • EPS 3 Yr Annual Growth Rate83%
  • EPS 3 Yr Growth Rank12
  • Total Return 3 Yr Annual Rate2%
  • Total Return 3 Yr Rank92

Jazz, which became an Irish company after its merger with Azur Pharma in 2012, has a drug portfolio focused on narcolepsy and hematology.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

Location
Dublin, Ireland
Industry
Pharmaceuticals
Sector
Health Care
Current Streak1
Years on List2
CEO
Bruce Cozadd
Websitehttp://www.jazzpharma.com
Revenue and net income for the four quarters ended on or before April 30, 2017. Total return for the period ended June 30, 2017.

Revenue, Net Income

Revenue past four quarters ($M)$1,528
Net Income past four quarters ($M)$408

Growth Rates and Ranks

Revenue 3 Yr Growth Rank88
Revenue 3 Yr Annual Growth Rate18%
EPS 3 Yr Growth Rank12
EPS 3 Yr Annual Growth Rate83%
Total Return 3 Yr Rank92
Total Return 3 Yr Annual Rate2%
Beat S&P 500 (9.6%)
no
P/E Ratio21